HS-10296 is primarily used in the field of oncology as a targeted therapy for non-small cell lung cancer (NSCLC). It functions as an EGFR tyrosine kinase inhibitor, effectively blocking the signaling pathways that promote cancer cell growth and proliferation. This makes it particularly effective in treating patients with EGFR mutations, which are common in certain types of lung cancer. Clinically, it has shown promise in improving progression-free survival and overall response rates in patients who have developed resistance to first-generation EGFR inhibitors. Its application is often considered in advanced or metastatic cases where traditional treatments have failed. Additionally, ongoing research explores its potential in other cancers with EGFR-related mutations.